Phase Advance’s Predictive Technology Platform is a modern sieve of AI & mathematical algorithms to identify medicines that will cure disease and become blockbusters – known as good black swan events – 7 to 14 years before clinical trials.
Our nonlinear modeling mimics biological systems, creating a biomechanistic engine from the molecular to the whole-body level, from cellular to tissue to organ to system to entire body, as well as their complex interactions. This virtual cradle-to-grave modeling simulates patient development and disease progression from birth through adulthood, enabling dynamic prediction of therapeutic responses.
Clinical trial success can be affected by unique population differences such as genomics and even diet. An Alzheimer’s patient with particular biomarkers could respond differently to the same drug that benefits a patient from another genetic background. Our multiscale data integration combines genetic, clinical, pharmacometric, and population data in one seamless analytical framework.
Whether clients use our models just after discovery or after preclinical work, we can compare the future trial endpoints to market leaders, help design better trials, and reduce the target sample size.
Phase Advance models can forecast with minimal details about the molecule or biologic in question, regardless of therapy class.
Post PRE-CLINICAL DRUG Development Phase
Immediately Post discovery
Our disease models align with the most in-demand therapeutic areas in biotech today, and are expanding continuously.
